Alex Mabou Tagne1, Barbara Pacchetti2, Mikael Sodergren2,3, Marco Cosentino1, Franca Marino1. 1. Center for Research in Medical Pharmacology, University of Insubria, Varese, Italy. 2. Emmac Life Sciences, London, United Kingdom. 3. Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
Abstract
Background: The possibility of cannabidiol (CBD) to be used as an antiviral or to treat viral diseases has received limited attention so far, despite the growing number of claims that CBD could be used for the treatment of viral infection-related conditions. Aim and Methods: Therefore, we systematically retrieved and critically evaluated the scientific literature available on PubMed and the claims on the Internet, to assess the current state of knowledge on the use of CBD in viral diseases, and to provide suggestions for future research directions. Results: PubMed search referenced two original articles supporting the use of CBD for the treatment of hepatitis C and Kaposi sarcoma and one article reporting the ability of CBD to reduce neuroinflammation in a virus-induced animal model of multiple sclerosis. Internet search found 25 websites claiming more indications for CBD. Remarkably, those claims were provided mostly by commercial websites and were not supported by appropriate scientific references. Conclusion: Although preclinical studies suggest the potential effectiveness of CBD in viral diseases such as hepatitis C and Kaposi sarcoma, clinical evidence is still lacking. Anecdotal experiences of CBD use retrieved on the Internet, on the other side, lack any support from sound scientific evidence, although they might in some cases provide suggestions for conditions associated with viral infections that may deserve proper assessment in well-designed clinical trials. Copyright 2020, Mary Ann Liebert, Inc., publishers.
Background: The possibility of cannabidiol (CBD) to be used as an antiviral or to treat viral diseases has received limited attention so far, despite the growing number of claims that CBD could be used for the treatment of viral infection-related conditions. Aim and Methods: Therefore, we systematically retrieved and critically evaluated the scientific literature available on PubMed and the claims on the Internet, to assess the current state of knowledge on the use of CBD in viral diseases, and to provide suggestions for future research directions. Results: PubMed search referenced two original articles supporting the use of CBD for the treatment of hepatitis C and Kaposi sarcoma and one article reporting the ability of CBD to reduce neuroinflammation in a virus-induced animal model of multiple sclerosis. Internet search found 25 websites claiming more indications for CBD. Remarkably, those claims were provided mostly by commercial websites and were not supported by appropriate scientific references. Conclusion: Although preclinical studies suggest the potential effectiveness of CBD in viral diseases such as hepatitis C and Kaposi sarcoma, clinical evidence is still lacking. Anecdotal experiences of CBD use retrieved on the Internet, on the other side, lack any support from sound scientific evidence, although they might in some cases provide suggestions for conditions associated with viral infections that may deserve proper assessment in well-designed clinical trials. Copyright 2020, Mary Ann Liebert, Inc., publishers.
Authors: Shanna Babalonis; Margaret Haney; Robert J Malcolm; Michelle R Lofwall; Victoria R Votaw; Steven Sparenborg; Sharon L Walsh Journal: Drug Alcohol Depend Date: 2016-12-14 Impact factor: 4.492
Authors: Celeste Lebbe; Claus Garbe; Alexander J Stratigos; Catherine Harwood; Ketty Peris; Veronique Del Marmol; Josep Malvehy; Iris Zalaudek; Christoph Hoeller; Reinhard Dummer; Ana Maria Forsea; Lidija Kandolf-Sekulovic; Judith Olah; Petr Arenberger; Matilda Bylaite-Bucinskiene; Ricardo Vieira; Mark Middleton; Antonin Levy; Alexander M Eggermont; Maxime Battistella; Jean Philippe Spano; Jean Jacques Grob; Cecile Pages Journal: Eur J Cancer Date: 2019-05-13 Impact factor: 9.162
Authors: D C Hammell; L P Zhang; F Ma; S M Abshire; S L McIlwrath; A L Stinchcomb; K N Westlund Journal: Eur J Pain Date: 2015-10-30 Impact factor: 3.931
Authors: Simona Pisanti; Anna Maria Malfitano; Elena Ciaglia; Anna Lamberti; Roberta Ranieri; Gaia Cuomo; Mario Abate; Giorgio Faggiana; Maria Chiara Proto; Donatella Fiore; Chiara Laezza; Maurizio Bifulco Journal: Pharmacol Ther Date: 2017-02-22 Impact factor: 12.310
Authors: Md Sultan Mahmud; Mohammad Sorowar Hossain; A T M Faiz Ahmed; Md Zahidul Islam; Md Emdad Sarker; Md Reajul Islam Journal: Molecules Date: 2021-11-28 Impact factor: 4.411
Authors: Dóra Révész; Genís Ona; Giordano N Rossi; Juliana M Rocha; Rafael G Dos Santos; Jaime E C Hallak; Miguel Á Alcázar-Córcoles; José C Bouso Journal: Front Psychiatry Date: 2021-06-16 Impact factor: 5.435